Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TYRO3 | Q06418 | 3/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | MERTK | Q12866 | 2/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19398124 | 0.90 | KDM4E (0.45) | KMT2AMETKDM4EGSK3AGSK3B | |
| SCHEMBL29625543 | 0.88 | KMT2A (0.48) | KMT2AMETKDM4EGSK3AGSK3B | |
| SCHEMBL19567654 | 0.88 | NOTUM (0.47) | KMT2ANOTUMALDH1A1METKDM4E | |
| SCHEMBL14967303 | 0.87 | NOTUM (0.47) | NOTUMMETMERTK | |
| SCHEMBL21785475 | 0.87 | NOTUM (0.47) | KMT2ANOTUMALDH1A1METKDM4E | |
| SCHEMBL23071267 | 0.87 | AXL (0.41) | KMT2AMETMERTK | |
| Hydrochloric Acid SCHEMBL31614377 | 0.87 | KMT2A (0.47) | KMT2AMETKDM4EGSK3AGSK3B | |
| SCHEMBL19377769 | 0.85 | ALKBH5 (0.43) | KMT2ANOTUMALDH1A1METGSK3A | |
| SCHEMBL23071280 | 0.85 | NOTUM (0.52) | NOTUMALDH1A1METTYRO3MERTK | |
| SCHEMBL23071007 | 0.85 | MET (0.44) | METKDM4EGSK3AGSK3BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2780338-B1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | IGNYTA INC (US) | 2016-11-09 | — | — | EP | claimed |
| US-20140275077-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. (US) | 2014-09-18 | — | — | US | claimed |
| US-20260042765-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORP (US) | 2026-02-12 | — | — | US | disclosed |
| US-12415809-B2 | Pyrrolotriazine compounds as tam inhibitors | INCYTE CORPORATION (US) | 2025-09-16 | — | — | US | disclosed |
| US-20250188086-A1 | SALTS OF TAM INHIBITORS | INCYTE CORPORATION | 2025-06-12 | — | — | US | disclosed |
| US-12187730-B2 | Salts of TAM inhibitors | INCYTE CORPORATION (US) | 2025-01-07 | — | — | US | disclosed |
| CN-118930549-A | Salts of pyrrolotriazine derivatives useful as TAM inhibitors | 因赛特公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-114456175-B | Pyrrolotriazine compounds as TAM inhibitors | 因赛特公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-114456176-B | Pyrrolotriazine compounds as TAM inhibitors | 因赛特公司 | 2024-08-30 | — | — | CN | disclosed |
| US-12037323-B2 | Uracil derivatives as Mer-AXL inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| CN-111386273-B | Salts of pyrrolotriazine derivatives useful as TAM inhibitors | 因赛特公司 | 2024-06-14 | — | — | CN | disclosed |
| EP-2780338-B1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | IGNYTA INC (US) | 2016-11-09 | — | — | EP | disclosed |
| EP-3045453-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. (US) | 2016-07-20 | — | — | EP | disclosed |
| US-9120778-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-20150210670-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. | 2015-07-30 | — | — | US | disclosed |
| US-20150209358-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. | 2015-07-30 | — | — | US | disclosed |
| US-9029538-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| EP-2780338-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | Cephalon, Inc. (US) | 2014-09-24 | — | — | EP | disclosed |
| US-20140275077-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2013074633-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042765-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | MAP2K2, TTK, MAP2K5 | KMT2A 806/4885NOTUM 1928/4885ALDH1A1 2069/4885 |
| US-12037323-B2 | Uracil derivatives as Mer-AXL inhibitors | MERTK, DAPK1, AXL | KMT2A 3563/4885NOTUM 4844/4885ALDH1A1 1072/4885 |
| US-20250188086-A1 | SALTS OF TAM INHIBITORS | PI4KA, PI4KB, PIK3CA | KMT2A 578/4885NOTUM 3709/4885ALDH1A1 3276/4885 |
| US-12187730-B2 | Salts of TAM inhibitors | PI4KA, PI4KB, PIK3CA | KMT2A 578/4885NOTUM 3709/4885ALDH1A1 3276/4885 |
| US-20150210670-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | AXL, RET, BRAF | KMT2A 822/4885NOTUM 4849/4885ALDH1A1 1561/4885 |
| US-12415809-B2 | Pyrrolotriazine compounds as tam inhibitors | MERTK, MAP3K15, MAP3K5 | KMT2A 640/4885NOTUM 4398/4885ALDH1A1 2279/4885 |
| US-20140275077-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | AXL, RET, BRAF | KMT2A 822/4885NOTUM 4849/4885ALDH1A1 1561/4885 |
| US-20150209358-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | AXL, RET, BRAF | KMT2A 822/4885NOTUM 4849/4885ALDH1A1 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.